nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—AR—polycystic ovary syndrome	0.887	1	CbGaD
Nilutamide—CYP2C19—urine—polycystic ovary syndrome	0.00678	0.126	CbGeAlD
Nilutamide—CYP2C9—urine—polycystic ovary syndrome	0.00525	0.0976	CbGeAlD
Nilutamide—POR—adrenal cortex—polycystic ovary syndrome	0.00328	0.0609	CbGeAlD
Nilutamide—Flutamide—AR—polycystic ovary syndrome	0.00309	0.395	CrCbGaD
Nilutamide—POR—endometrium—polycystic ovary syndrome	0.00293	0.0544	CbGeAlD
Nilutamide—Enzalutamide—AR—polycystic ovary syndrome	0.00282	0.361	CrCbGaD
Nilutamide—POR—pituitary gland—polycystic ovary syndrome	0.00265	0.0492	CbGeAlD
Nilutamide—POR—adipose tissue—polycystic ovary syndrome	0.00264	0.049	CbGeAlD
Nilutamide—POR—adrenal gland—polycystic ovary syndrome	0.00237	0.044	CbGeAlD
Nilutamide—POR—female gonad—polycystic ovary syndrome	0.00221	0.041	CbGeAlD
Nilutamide—POR—vagina—polycystic ovary syndrome	0.00219	0.0407	CbGeAlD
Nilutamide—POR—endocrine gland—polycystic ovary syndrome	0.00205	0.0381	CbGeAlD
Nilutamide—AR—adrenal cortex—polycystic ovary syndrome	0.00194	0.036	CbGeAlD
Nilutamide—Flutamide—CYP1A1—polycystic ovary syndrome	0.0019	0.243	CrCbGaD
Nilutamide—AR—endometrium—polycystic ovary syndrome	0.00173	0.0321	CbGeAlD
Nilutamide—AR—uterus—polycystic ovary syndrome	0.00159	0.0296	CbGeAlD
Nilutamide—AR—pituitary gland—polycystic ovary syndrome	0.00157	0.0291	CbGeAlD
Nilutamide—AR—adipose tissue—polycystic ovary syndrome	0.00156	0.029	CbGeAlD
Nilutamide—CYP2C8—endometrium—polycystic ovary syndrome	0.0014	0.026	CbGeAlD
Nilutamide—AR—adrenal gland—polycystic ovary syndrome	0.0014	0.026	CbGeAlD
Nilutamide—AR—female gonad—polycystic ovary syndrome	0.0013	0.0242	CbGeAlD
Nilutamide—AR—vagina—polycystic ovary syndrome	0.0013	0.0241	CbGeAlD
Nilutamide—CYP2C8—pituitary gland—polycystic ovary syndrome	0.00127	0.0235	CbGeAlD
Nilutamide—AR—endocrine gland—polycystic ovary syndrome	0.00121	0.0225	CbGeAlD
Nilutamide—CYP2C19—vagina—polycystic ovary syndrome	0.0012	0.0223	CbGeAlD
Nilutamide—CYP2C19—endocrine gland—polycystic ovary syndrome	0.00112	0.0209	CbGeAlD
Nilutamide—CYP2C8—vagina—polycystic ovary syndrome	0.00105	0.0195	CbGeAlD
Nilutamide—CYP2C8—endocrine gland—polycystic ovary syndrome	0.000981	0.0182	CbGeAlD
Nilutamide—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000871	0.0162	CbGeAlD
Nilutamide—CYP2C8—Arachidonic acid metabolism—CYP1A1—polycystic ovary syndrome	0.000173	0.00346	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—SERPINE1—polycystic ovary syndrome	0.000172	0.00342	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP17A1—polycystic ovary syndrome	0.00017	0.00339	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—polycystic ovary syndrome	0.000167	0.00333	CbGpPWpGaD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—polycystic ovary syndrome	0.000166	0.00331	CbGpPWpGaD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—polycystic ovary syndrome	0.000164	0.00327	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—BAX—polycystic ovary syndrome	0.000157	0.00314	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP17A1—polycystic ovary syndrome	0.000155	0.00309	CbGpPWpGaD
Nilutamide—CYP2C19—Arachidonic acid metabolism—CYP1A1—polycystic ovary syndrome	0.000155	0.00309	CbGpPWpGaD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—polycystic ovary syndrome	0.000151	0.00302	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.000151	0.00301	CbGpPWpGaD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.00015	0.00299	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—polycystic ovary syndrome	0.000149	0.00298	CbGpPWpGaD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.000148	0.00295	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—NR3C1—polycystic ovary syndrome	0.000146	0.0029	CbGpPWpGaD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—polycystic ovary syndrome	0.000145	0.0029	CbGpPWpGaD
Nilutamide—AR—Gene Expression—LSM5—polycystic ovary syndrome	0.000143	0.00285	CbGpPWpGaD
Nilutamide—CYP2C9—Arachidonic acid metabolism—CYP1A1—polycystic ovary syndrome	0.000141	0.00282	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.000135	0.00268	CbGpPWpGaD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.000134	0.00267	CbGpPWpGaD
Nilutamide—AR—Gene Expression—SAP30L—polycystic ovary syndrome	0.000133	0.00265	CbGpPWpGaD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.000132	0.00263	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.000132	0.00263	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—BAX—polycystic ovary syndrome	0.00013	0.0026	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.000123	0.00245	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.000123	0.00245	CbGpPWpGaD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.000122	0.00243	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	0.000122	0.00242	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	0.000121	0.00242	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.00012	0.0024	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—IRS1—polycystic ovary syndrome	0.000119	0.00236	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.000118	0.00234	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—LPCAT2—polycystic ovary syndrome	0.000117	0.00233	CbGpPWpGaD
Nilutamide—AR—Gene Expression—TEAD2—polycystic ovary syndrome	0.000113	0.00225	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—YAP1—polycystic ovary syndrome	0.000112	0.00223	CbGpPWpGaD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	0.000112	0.00223	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.00011	0.00219	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP11A1—polycystic ovary syndrome	0.000109	0.00217	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	0.000108	0.00216	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	0.000108	0.00216	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	0.000107	0.00214	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.000107	0.00214	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—LPCAT2—polycystic ovary syndrome	0.000104	0.00208	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	0.000101	0.00202	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP17A1—polycystic ovary syndrome	0.000101	0.00202	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.0001	0.00199	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	9.98e-05	0.00199	CbGpPWpGaD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	9.98e-05	0.00199	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	9.89e-05	0.00197	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	9.87e-05	0.00197	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—PGR—polycystic ovary syndrome	9.78e-05	0.00195	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP11A1—polycystic ovary syndrome	9.72e-05	0.00194	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—BCL2—polycystic ovary syndrome	9.59e-05	0.00191	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	9.58e-05	0.00191	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—LPCAT2—polycystic ovary syndrome	9.49e-05	0.00189	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	9.22e-05	0.00184	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	9.22e-05	0.00184	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	9.1e-05	0.00182	CbGpPWpGaD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	9.1e-05	0.00181	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	9.06e-05	0.00181	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	9.05e-05	0.00181	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP17A1—polycystic ovary syndrome	9.03e-05	0.0018	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	8.91e-05	0.00178	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP11A1—polycystic ovary syndrome	8.86e-05	0.00177	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	8.74e-05	0.00174	CbGpPWpGaD
Nilutamide—Influenza—Metformin—polycystic ovary syndrome	8.48e-05	0.0512	CcSEcCtD
Nilutamide—Angina pectoris—Metformin—polycystic ovary syndrome	8.26e-05	0.0499	CcSEcCtD
Nilutamide—CYP2C9—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	8.25e-05	0.00165	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP17A1—polycystic ovary syndrome	8.24e-05	0.00164	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	8.23e-05	0.00164	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	8.23e-05	0.00164	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	8.12e-05	0.00162	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	8.09e-05	0.00161	CbGpPWpGaD
Nilutamide—AR—Gene Expression—RPL37A—polycystic ovary syndrome	8.04e-05	0.0016	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP19A1—polycystic ovary syndrome	8.01e-05	0.0016	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	7.95e-05	0.00158	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	7.9e-05	0.00158	CbGpPWpGaD
Nilutamide—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	7.88e-05	0.0476	CcSEcCtD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	7.73e-05	0.00154	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	7.5e-05	0.0015	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	7.5e-05	0.0015	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	7.38e-05	0.00147	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	7.32e-05	0.00146	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—VEGFA—polycystic ovary syndrome	7.17e-05	0.00143	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP19A1—polycystic ovary syndrome	7.15e-05	0.00143	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	7.05e-05	0.00141	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	6.99e-05	0.00139	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	6.99e-05	0.00139	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	6.9e-05	0.00138	CbGpPWpGaD
Nilutamide—Rhinitis—Metformin—polycystic ovary syndrome	6.8e-05	0.0411	CcSEcCtD
Nilutamide—Hypoaesthesia—Metformin—polycystic ovary syndrome	6.75e-05	0.0408	CcSEcCtD
Nilutamide—Oedema peripheral—Metformin—polycystic ovary syndrome	6.68e-05	0.0404	CcSEcCtD
Nilutamide—AR—Generic Transcription Pathway—NCOR1—polycystic ovary syndrome	6.65e-05	0.00133	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	6.54e-05	0.0013	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP19A1—polycystic ovary syndrome	6.52e-05	0.0013	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP1A1—polycystic ovary syndrome	6.46e-05	0.00129	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	6.43e-05	0.00128	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	6.37e-05	0.00127	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	6.29e-05	0.00125	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	6.24e-05	0.00124	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—NR3C1—polycystic ovary syndrome	6.15e-05	0.00123	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	5.96e-05	0.00119	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	5.95e-05	0.00119	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	5.94e-05	0.00118	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP1A1—polycystic ovary syndrome	5.76e-05	0.00115	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	5.69e-05	0.00113	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	5.68e-05	0.00113	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NMNAT3—polycystic ovary syndrome	5.68e-05	0.00113	CbGpPWpGaD
Nilutamide—Ill-defined disorder—Metformin—polycystic ovary syndrome	5.48e-05	0.0331	CcSEcCtD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	5.42e-05	0.00108	CbGpPWpGaD
Nilutamide—AR—Gene Expression—YAP1—polycystic ovary syndrome	5.39e-05	0.00108	CbGpPWpGaD
Nilutamide—Malaise—Metformin—polycystic ovary syndrome	5.33e-05	0.0322	CcSEcCtD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	5.3e-05	0.00106	CbGpPWpGaD
Nilutamide—Syncope—Metformin—polycystic ovary syndrome	5.3e-05	0.032	CcSEcCtD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	5.3e-05	0.00106	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP1A1—polycystic ovary syndrome	5.25e-05	0.00105	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—LPCAT2—polycystic ovary syndrome	5.19e-05	0.00104	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—SUOX—polycystic ovary syndrome	5.19e-05	0.00104	CbGpPWpGaD
Nilutamide—Loss of consciousness—Metformin—polycystic ovary syndrome	5.19e-05	0.0314	CcSEcCtD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	5.18e-05	0.00103	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	5.13e-05	0.00102	CbGpPWpGaD
Nilutamide—Hypertension—Metformin—polycystic ovary syndrome	5.1e-05	0.0308	CcSEcCtD
Nilutamide—CYP2C19—Metabolism—NMNAT3—polycystic ovary syndrome	5.07e-05	0.00101	CbGpPWpGaD
Nilutamide—Chest pain—Metformin—polycystic ovary syndrome	5.03e-05	0.0304	CcSEcCtD
Nilutamide—Discomfort—Metformin—polycystic ovary syndrome	4.97e-05	0.03	CcSEcCtD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	4.84e-05	0.000964	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	4.84e-05	0.000964	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	4.83e-05	0.000964	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ISYNA1—polycystic ovary syndrome	4.83e-05	0.000963	CbGpPWpGaD
Nilutamide—Oedema—Metformin—polycystic ovary syndrome	4.82e-05	0.0291	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—POMC—polycystic ovary syndrome	4.81e-05	0.00096	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—PPARG—polycystic ovary syndrome	4.77e-05	0.00095	CbGpPWpGaD
Nilutamide—AR—Gene Expression—TNRC6B—polycystic ovary syndrome	4.76e-05	0.000949	CbGpPWpGaD
Nilutamide—Shock—Metformin—polycystic ovary syndrome	4.74e-05	0.0287	CcSEcCtD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	4.73e-05	0.000943	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	4.72e-05	0.000941	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PGR—polycystic ovary syndrome	4.71e-05	0.000939	CbGpPWpGaD
Nilutamide—Hyperhidrosis—Metformin—polycystic ovary syndrome	4.66e-05	0.0282	CcSEcCtD
Nilutamide—CYP2C19—Metabolism—LPCAT2—polycystic ovary syndrome	4.64e-05	0.000925	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—SUOX—polycystic ovary syndrome	4.64e-05	0.000925	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NMNAT3—polycystic ovary syndrome	4.62e-05	0.000922	CbGpPWpGaD
Nilutamide—Anorexia—Metformin—polycystic ovary syndrome	4.59e-05	0.0278	CcSEcCtD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	4.58e-05	0.000913	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	4.41e-05	0.000879	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	4.41e-05	0.000879	CbGpPWpGaD
Nilutamide—Paraesthesia—Metformin—polycystic ovary syndrome	4.33e-05	0.0262	CcSEcCtD
Nilutamide—CYP2C19—Metabolism—ISYNA1—polycystic ovary syndrome	4.31e-05	0.00086	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	4.31e-05	0.00086	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—POMC—polycystic ovary syndrome	4.3e-05	0.000857	CbGpPWpGaD
Nilutamide—Dyspnoea—Metformin—polycystic ovary syndrome	4.3e-05	0.026	CcSEcCtD
Nilutamide—AR—Generic Transcription Pathway—SERPINE1—polycystic ovary syndrome	4.29e-05	0.000856	CbGpPWpGaD
Nilutamide—Dyspepsia—Metformin—polycystic ovary syndrome	4.24e-05	0.0256	CcSEcCtD
Nilutamide—CYP2C9—Metabolism—SUOX—polycystic ovary syndrome	4.23e-05	0.000843	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—LPCAT2—polycystic ovary syndrome	4.23e-05	0.000843	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	4.21e-05	0.00084	CbGpPWpGaD
Nilutamide—Decreased appetite—Metformin—polycystic ovary syndrome	4.19e-05	0.0253	CcSEcCtD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	4.18e-05	0.000834	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	4.17e-05	0.000832	CbGpPWpGaD
Nilutamide—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	4.16e-05	0.0251	CcSEcCtD
Nilutamide—Constipation—Metformin—polycystic ovary syndrome	4.12e-05	0.0249	CcSEcCtD
Nilutamide—CYP2C8—Metabolism—AKR1C2—polycystic ovary syndrome	4.11e-05	0.000819	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—TEAD2—polycystic ovary syndrome	4.11e-05	0.000819	CbGpPWpGaD
Nilutamide—Feeling abnormal—Metformin—polycystic ovary syndrome	3.97e-05	0.024	CcSEcCtD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	3.95e-05	0.000787	CbGpPWpGaD
Nilutamide—Gastrointestinal pain—Metformin—polycystic ovary syndrome	3.94e-05	0.0238	CcSEcCtD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	3.93e-05	0.000784	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ISYNA1—polycystic ovary syndrome	3.93e-05	0.000784	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—POMC—polycystic ovary syndrome	3.92e-05	0.000781	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	3.89e-05	0.000775	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	3.84e-05	0.000766	CbGpPWpGaD
Nilutamide—Abdominal pain—Metformin—polycystic ovary syndrome	3.81e-05	0.023	CcSEcCtD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	3.73e-05	0.000744	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—TEAD2—polycystic ovary syndrome	3.67e-05	0.000731	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—AKR1C2—polycystic ovary syndrome	3.67e-05	0.000731	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	3.59e-05	0.000715	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	3.52e-05	0.000703	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	3.47e-05	0.000692	CbGpPWpGaD
Nilutamide—Asthenia—Metformin—polycystic ovary syndrome	3.46e-05	0.0209	CcSEcCtD
Nilutamide—CYP2C8—Metabolism—PNPLA2—polycystic ovary syndrome	3.44e-05	0.000686	CbGpPWpGaD
Nilutamide—Pruritus—Metformin—polycystic ovary syndrome	3.41e-05	0.0206	CcSEcCtD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	3.4e-05	0.000679	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—TEAD2—polycystic ovary syndrome	3.34e-05	0.000666	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—AKR1C2—polycystic ovary syndrome	3.34e-05	0.000666	CbGpPWpGaD
Nilutamide—Diarrhoea—Metformin—polycystic ovary syndrome	3.3e-05	0.0199	CcSEcCtD
Nilutamide—CYP2C8—Metabolism—SRD5A1—polycystic ovary syndrome	3.26e-05	0.000651	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	3.21e-05	0.000641	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NCOR1—polycystic ovary syndrome	3.2e-05	0.000639	CbGpPWpGaD
Nilutamide—Dizziness—Metformin—polycystic ovary syndrome	3.19e-05	0.0193	CcSEcCtD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	3.16e-05	0.000631	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—STAR—polycystic ovary syndrome	3.11e-05	0.000621	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	3.08e-05	0.000613	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PNPLA2—polycystic ovary syndrome	3.07e-05	0.000613	CbGpPWpGaD
Nilutamide—Vomiting—Metformin—polycystic ovary syndrome	3.06e-05	0.0185	CcSEcCtD
Nilutamide—Rash—Metformin—polycystic ovary syndrome	3.04e-05	0.0184	CcSEcCtD
Nilutamide—Dermatitis—Metformin—polycystic ovary syndrome	3.04e-05	0.0183	CcSEcCtD
Nilutamide—Headache—Metformin—polycystic ovary syndrome	3.02e-05	0.0182	CcSEcCtD
Nilutamide—AR—Gene Expression—NR3C1—polycystic ovary syndrome	2.96e-05	0.000591	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—SRD5A1—polycystic ovary syndrome	2.91e-05	0.000581	CbGpPWpGaD
Nilutamide—Nausea—Metformin—polycystic ovary syndrome	2.86e-05	0.0173	CcSEcCtD
Nilutamide—CYP2C9—Metabolism—PNPLA2—polycystic ovary syndrome	2.8e-05	0.000558	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—STAR—polycystic ovary syndrome	2.78e-05	0.000554	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—HMMR—polycystic ovary syndrome	2.77e-05	0.000553	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	2.75e-05	0.000548	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—SRD5A1—polycystic ovary syndrome	2.65e-05	0.000529	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—HSD3B1—polycystic ovary syndrome	2.65e-05	0.000528	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	2.62e-05	0.000522	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—STAR—polycystic ovary syndrome	2.53e-05	0.000505	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	2.5e-05	0.000499	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	2.48e-05	0.000494	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—HMMR—polycystic ovary syndrome	2.48e-05	0.000494	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—LHB—polycystic ovary syndrome	2.41e-05	0.000481	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—HSD3B1—polycystic ovary syndrome	2.36e-05	0.000471	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—HSD3B2—polycystic ovary syndrome	2.36e-05	0.00047	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	2.33e-05	0.000466	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PPARG—polycystic ovary syndrome	2.29e-05	0.000458	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—AKR1C1—polycystic ovary syndrome	2.28e-05	0.000456	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—HMMR—polycystic ovary syndrome	2.26e-05	0.00045	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	2.21e-05	0.000441	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—LHB—polycystic ovary syndrome	2.15e-05	0.00043	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—HSD3B1—polycystic ovary syndrome	2.15e-05	0.000429	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	2.13e-05	0.000425	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—HSD3B2—polycystic ovary syndrome	2.11e-05	0.00042	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—SULT2A1—polycystic ovary syndrome	2.1e-05	0.000419	CbGpPWpGaD
Nilutamide—AR—Gene Expression—SERPINE1—polycystic ovary syndrome	2.07e-05	0.000412	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—AKR1C1—polycystic ovary syndrome	2.04e-05	0.000407	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—RRM2—polycystic ovary syndrome	2.04e-05	0.000406	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	2.02e-05	0.000402	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	1.96e-05	0.000392	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—YAP1—polycystic ovary syndrome	1.96e-05	0.000391	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	1.92e-05	0.000383	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NAMPT—polycystic ovary syndrome	1.89e-05	0.000376	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	1.88e-05	0.000374	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.87e-05	0.000374	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP11A1—polycystic ovary syndrome	1.86e-05	0.000371	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	1.86e-05	0.000371	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.85e-05	0.000369	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	1.82e-05	0.000362	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—AKR1C3—polycystic ovary syndrome	1.76e-05	0.000351	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	1.75e-05	0.000349	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP17A1—polycystic ovary syndrome	1.73e-05	0.000345	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	1.71e-05	0.000341	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	1.68e-05	0.000336	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.67e-05	0.000334	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	1.66e-05	0.000331	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	1.66e-05	0.00033	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.65e-05	0.000329	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	1.6e-05	0.000319	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	1.57e-05	0.000313	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	1.55e-05	0.000308	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	1.53e-05	0.000306	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.53e-05	0.000304	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	1.52e-05	0.000302	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.5e-05	0.0003	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—TH—polycystic ovary syndrome	1.5e-05	0.000299	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	1.46e-05	0.000291	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	1.43e-05	0.000285	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	1.41e-05	0.000281	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	1.37e-05	0.000273	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—TH—polycystic ovary syndrome	1.34e-05	0.000267	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	1.3e-05	0.000259	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	1.22e-05	0.000244	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	1.22e-05	0.000244	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—TH—polycystic ovary syndrome	1.22e-05	0.000243	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	1.19e-05	0.000236	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	1.16e-05	0.000232	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	1.11e-05	0.000222	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	1.1e-05	0.00022	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	1.09e-05	0.000218	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	1.04e-05	0.000207	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	1.03e-05	0.000205	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	9.95e-06	0.000198	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	9.86e-06	0.000197	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	9.48e-06	0.000189	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	9.19e-06	0.000183	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	8.99e-06	0.000179	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	8.38e-06	0.000167	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	8.35e-06	0.000166	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	8.23e-06	0.000164	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—INS—polycystic ovary syndrome	8.19e-06	0.000163	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	7.45e-06	0.000149	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	7.35e-06	0.000147	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—INS—polycystic ovary syndrome	7.31e-06	0.000146	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	6.79e-06	0.000135	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	6.7e-06	0.000134	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—INS—polycystic ovary syndrome	6.66e-06	0.000133	CbGpPWpGaD
